The unique database includes more than 600 billion different molecules obtained from 1758 donors. The project is implemented since 2014 by BIOCAD, a biotechnology company. This is their second library of human antibodies. Earlier, the researchers from BIOCAD presented to the world scientific community Meganlib, a scFv library that included antibodies obtained from 1000 donors. Both libraries are used to develop the new generation of drugs used in the therapy of socially important diseases.
“In combination with high-performance analysis techniques and optimization technologies with the help of mathematical modeling, the use of the most diverse libraries of antibodies allows to accelerate the launch of new drugs and, therefore, improve the availability of advanced therapy to the patients. For example, the antibodies from our Meganlib, a Fab library, helped to create BCD-100, a fully human antibody to PD1 receptor. The new library is already being used to develop new drugs against oncological and autoimmune diseases,” said Timofey Nemankin, the Head of Antibody Development Department at BIOCAD.
Today, there are three known types of antibody libraries. Outside Russia, there are synthetic libraries that include samples of molecules synthesized from oligonucleotides, and immune libraries with the samples based on animal biomaterial. The most known collections are held by Pfizer, Medimmune, and MorphoSys.